Case Study | Acute Coronary Syndrome

65 cardiovascular sites. 2 to 3 days to feasibility.

How AcceleTrial compressed feasibility timelines for a global ACS trial with an innovative LDL-lowering drug, exceeding the sponsor's site targets and turnaround expectations.

65
Sites Identified
2-3 Days
Feasibility Turnaround
46
Sites Selected
50%
Faster Documents

The Challenge

60 cardiovascular sites for LDL-lowering drug trial

Identifying sites with cardiovascular expertise, patient access, and operational readiness for an ACS study.

Acquiring CDAs and FQs under compression

Communicating with a large number of sites and executing study documents within a compressed schedule.

Timely activation to accelerate trial timeline

Activating sites quickly to prevent downstream delays in the overall study schedule.

The Solution

Using AcceleTrial, LINEA identified 65 sites with cardiovascular trial expertise. Feasibility and CDAs were completed in 2 to 3 days, exceeding the sponsor's expectations. All documents were collected at a 50% faster rate. Sites were evaluated against trial history, COVID-readiness, debarment, and clinical experience.

Site Criteria

Cardiovascular Clinical ExperienceTrial HistoryCOVID-ReadinessDebarment CheckPatient Access

Outcomes

65 Sites Identified

Exceeded sponsor target of 60, with full qualification against cardiovascular protocol criteria.

2-3 Day Turnaround

Feasibility and CDAs completed in 2 to 3 days, exceeding the sponsor's stated expectations.

46 Sites Selected

46 LINEA sites selected for inclusion in the ACS study.